Loading...
•
Dec 31, 2025
Tango Therapeutics Q4 2025 Earnings Report
Tango Therapeutics reported no revenue in Q4 2025 and continued operating losses as it advanced its clinical-stage oncology pipeline.
Key Takeaways
Tango Therapeutics reported no revenue for the fourth quarter of 2025 as collaboration revenue ended following the Gilead agreement truncation. The company recorded a net loss of 38749000 while continuing to invest in research and development programs including vopimetostat and other oncology pipeline candidates.
Total revenue for Q4 2025 was 0 compared with 5431000 in Q4 2024.
Net loss widened to 38749000 driven by ongoing R&D investment in oncology programs.
Research and development expenses reached 32101000 as the company advanced multiple pipeline candidates.
Cash, cash equivalents and marketable securities totaled approximately 343100000 at year end providing runway into 2028.
Forward Guidance
Tango Therapeutics expects its cash position to fund operations into 2028 while advancing clinical programs including vopimetostat and TNG456 with multiple clinical data milestones expected in 2026.
Positive Outlook
- Cash runway expected to extend into 2028.
- Phase 1/2 combination trial data for vopimetostat with RAS inhibitors expected in 2026.
- Planned pivotal study for vopimetostat monotherapy in second-line pancreatic cancer.
- Additional clinical data updates expected from TNG456 and other pipeline programs.
- New collaboration with Erasca to evaluate combination therapy opportunities.
Challenges Ahead
- Company generated no revenue during the quarter.
- Net losses remain significant due to ongoing clinical development costs.
- High dependence on external funding and partnerships.
- Clinical-stage pipeline carries regulatory and development risks.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...